Related Experiment Videos
Halofenate in the treatment of type II hyperlipoproteinemia. Double blind comparison with clofibrate
Insights
Halofenate showed comparable cholesterol response rates but less magnitude compared to clofibrate in hyperlipoproteinemia patients. Clofibrate was more effective for lowering triglycerides, with weight gain impacting cholesterol reduction.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Type II hyperlipoproteinemia is a condition characterized by elevated cholesterol and triglyceride levels.
- Vascular disease is a common comorbidity in patients with hyperlipoproteinemia.
- Lipid-lowering drugs like clofibrate are established treatments for hyperlipoproteinemia.
Purpose of the Study:
- To compare the efficacy of a new lipid-lowering drug, halofenate, with clofibrate.
- To evaluate the effects of these drugs on serum cholesterol and triglyceride levels in patients with Type II hyperlipoproteinemia.
Main Methods:
- A double-blind study involving 33 patients with Type II hyperlipoproteinemia.
- Patients were treated for 48-96 weeks with either halofenate or clofibrate.
- Serum lipid levels (cholesterol and triglycerides) were monitored throughout the study.
Main Results:
- Comparable proportions of patients responded to both halofenate and clofibrate for cholesterol reduction (56-59%), but halofenate responders showed a smaller mean decrease (12% vs. 25%).
- Clofibrate responders had a higher response rate for triglyceride lowering (87% vs. 57% for halofenate), with comparable magnitude of reduction.
- Weight gain of 5% or more negatively impacted cholesterol lowering, while triglyceride lowering was less affected.
- Type IIa patients were more likely to respond favorably to cholesterol reduction than Type IIb patients.
Conclusions:
- Halofenate is less effective than clofibrate in reducing cholesterol magnitude and triglyceride response in Type II hyperlipoproteinemia.
- Weight management may be crucial for optimizing cholesterol-lowering treatment outcomes.
- Further research is warranted to explore the full potential of halofenate and optimize its use in managing hyperlipoproteinemia.
Abstract:
A double-blind study comparing halofenate, a new lipid-lowering investigation drug, with an established drug, clofibrate, was conducted on 33 clinic patients with Type II hyperlipoproteinemia for a period of 48-96 weeks. All but 10 patients had some type of symptomatic major vascular disease. With respect to serum cholesterol levels, a comparable proportion (56-59%) of patients in each group responded to the respective treatment but the magnitude of lowering was substantially less for the halofenate responders (12% mean decrease versus 25%). Type IIa patients in both groups were more likely than Type IIb patients to have a favorable cholesterol-lowering response. Weight gain of 5% or greater was prejudicial to cholesterol lowering. In the case of serum triglycerides, the proportion of patients responding to clofibrate treatment was somewhat greater (87% versus 57% for halofenate) but the mean magnitude of lowering (27-34%) was comparable for responders in the two groups. Weight gain did not influence appreciably the triglyceride-lowering effect. Elevated concentrations of triglyceride (Type IIb) in the control period favored a triglyceride lowering response by clofibrate but was only a moderate influence on the response to halofenate.